Peptide receptor radionuclide therapy (PRRT) is an established treatment for grade 1 and 2
gastroenteropancreatic neuroendocrine tumors with an increased uptake on somatostatin …

Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …

Introduction: Since the initial approval of everolimus in 2011, there have been a number of
important changes in therapeutic/diagnostic modalities as well as classification/staging …

This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …

This ENETS guidance paper for well‐differentiated nonfunctioning pancreatic
neuroendocrine tumours (NF‐Pan‐NET) has been developed by a multidisciplinary working …

Purpose: Patients with pancreatic neuroendocrine neoplasm grade-3 (PanNEN-G3) show
variable responses to platinum-based chemotherapy. Recent studies indicated that PanNEN …

Aim To test radiomic approach in patients with metastatic neuroendocrine tumors (NETs)
treated with Everolimus, with the aim to predict progression-free survival (PFS) and death …

High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are classified
according to morphology as well-differentiated neuroendocrine tumours (NETs) G3 or poorly …

High-grade neuroendocrine neoplasms are a rare disease entity and account for
approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an …

Abstract Purpose Grade 3 NENs are aggressive tumours with poor prognosis. PRRT+/−
radiosensitising chemotherapy is a potential treatment for disease with high somatostatin …